BioXcel Therapeutics IncBTAI
Price$0.07

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $742K-67.3% YoYTTM through 30 Jun 2026
Net Income -$70.9MTTM through 30 Jun 2026
Free Cash Flow -$50.9MTTM through 30 Jun 2026

Margins

Current
Gross Margin-37.4%
Operating Margin-4,951.5%
Net Margin-9,549.9%

Returns

61.4%ROE

Balance Sheet Health

Current Ratio0.62x
Net Debt$83.1M
Cash & Equivalents$12.8M

Quality Metrics

Altman Z-Score-45.97
Piotroski F-Score2 / 9
FCF Margin-6,860.4%
Rule of 40-6,856.6
Earnings-Beat Rate0.0%

Multi-Year Trend

Revenue
'22'23'24'25
FY2025: $642K
Diluted EPS
'20'21'22'23'24'25
FY2025: $-5.73

Dividend

No dividend

Capital Allocation

Capex Intensity0.0%

Segment Performance

No segment data available.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.